About ABL Bio
ABL Bio is a company based in Seongnam-si (South Korea) founded in 2016. It operates as a HealthTech. ABL Bio has raised $65 million across 2 funding rounds from investors including DSC Investment, Hana Financial Group and DS Asset. The company has 104 employees as of December 31, 2024. ABL Bio offers products and services including ABL301, ABL503, and ABL111. ABL Bio operates in a competitive market with competitors including argenx, MacroGenics, TScan Therapeutics, Lyell Immunopharma and Alexion, among others.
- Headquarter Seongnam-si, South Korea
- Employees 104 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abl Bio, Inc.
-
Annual Revenue
$22.65 M (USD)-49.04as on Dec 31, 2024
-
Net Profit
-$37.65 M (USD)-1998.09as on Dec 31, 2024
-
EBITDA
-$38.63 M (USD)-208401.84as on Dec 31, 2024
-
Total Equity Funding
$65 M (USD)
in 2 rounds
-
Latest Funding Round
$65 M (USD), Series C
Jun 09, 2018
-
Investors
DSC Investment
& 3 more
-
Employee Count
104
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ABL Bio
ABL Bio is a publicly listed company on the KRX with ticker symbol 298380 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ABL Bio
ABL Bio offers a comprehensive portfolio of products and services, including ABL301, ABL503, and ABL111.
Developed as a treatment for neurodegenerative brain diseases.
Designed as an immuno-oncology therapy for cancer treatment.
Created for gastric cancer as a primary treatment.
People of ABL Bio
Unlock access to complete
Unlock access to complete
Funding Insights of ABL Bio
ABL Bio has successfully raised a total of $65M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $65 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $65.0M
- First Round First Round
- Investors Count 4
Investors in ABL Bio
ABL Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include DSC Investment, Hana Financial Group and DS Asset.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested primarily in South Korean startups.
|
Founded Year | Domain | Location | |
|
DS Asset is engaged in asset management and investment services.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by ABL Bio
Financial Statements - ABL Bio
Abl Bio Comparisons
Competitors of ABL Bio
ABL Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, TScan Therapeutics, Lyell Immunopharma and Alexion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
Frequently Asked Questions about ABL Bio
ABL Bio was founded in 2016.
ABL Bio is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
ABL Bio is a funded company, having raised a total of $65M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at ABL Bio is 104.
Annual revenue of ABL Bio is $22.65M as on Dec 31, 2024.
ABL Bio is focused on the development of innovative biopharmaceuticals targeting challenging diseases such as cancer and neurodegenerative brain disorders. The company is recognized for its dual-antibody platforms, which are utilized in immuno-oncology therapies, neurodegenerative disease treatments, and antibody-drug conjugates (ADCs). Solutions are developed to address low response rates in cancer treatments, enhance brain delivery for neurological therapies, and improve therapeutic indices for rare blood cancers. The sectors served include healthcare and biotechnology, with a strong emphasis on research and clinical advancements.
ABL Bio's top competitors include argenx, Hummingbird Bioscience and Lyell Immunopharma.
ABL Bio offers ABL301, ABL503, and ABL111.
Yes, ABL Bio is publicly traded on KRX under the ticker symbol 298380.
ABL Bio has 4 investors. Key investors include DSC Investment, Hana Financial Group, DS Asset, and QUAD.
The ticker symbol of ABL Bio is 298380 on KRX.